Desupervised and Red Glead Discovery receive Eurostars R&D grant to deliver AI-based tool for Drug Discovery
Copenhagen, Denmark and Lund, Sweden February 22nd, 2022
In this unique strategic partnership, Desupervised and Red Glead Discovery join forces to create robust AI-based solutions enabling companies to reduce cost and time in small molecule drug research and development.
Capitalizing on its proprietary AI-platform, Desupervised will leverage Bayesian deep learning models that quantify uncertainty for more reliable prediction of novel molecular structures for drug discovery projects. Such models need less data for training and enable domain knowledge inclusion, making drug discovery easier and faster. Currently, first-generation AI-tools that are being adopted by large Pharma companies require a significant investment in both implementing and operating such tools. Besides its technical advantages, AId (AId stands for a novel artificial intelligence-based tool for Drug Discovery) will be easy to implement also for smaller organizations to achieve significant improvement of workflows facilitated by AI technology.
Red Glead Discovery, providing integrated drug discovery services, has delivered several small molecule candidate drugs for progress to clinical trials in CNS and cancer indications to clients. Combining the partners´ expert knowledge from entirely different sectors, drug discovery and artificial intelligence (AI), the AId project aims at introducing an entirely new product to the market.
Johan Evenäs, CEO Red Glead Discovery AB says: “The collaboration with Desupervised fits perfectly with our strategy to become a leading and sustainable European drug discovery company. While RGD’s service platform increasingly attracts international biotech and large, global pharmaceutical companies, we are keen to extend and improve our service offer with AI technology. This project enables us to contribute with our expert knowledge in small molecule drug discovery to co-develop and implement state-of-the art AI tools, empowering us to better respond to future client needs.”
The CEO of Desupervised, Michael Green, adds: “I am delighted to be able to embark on this project, which will enable companies to innovate at greater speed utilizing AI and Machine Learning. We’ve always been about making AI usage accessible, robust and sustainable through our core Alvíss AI platform which is deployed in a variety of sectors today. In this project, we leverage the deep knowledge Red Glead Discovery has about the drug discovery process to build a new democratized drug discovery tool.”
About Red Glead Discovery AB
Red Glead Discovery is a leading Scandinavian provider for integrated drug discovery contract research and supports customers in the Life Science industry to develop their ideas for new drugs. www.redglead.com
About Desupervised ApS
Desupervised is a Nordic AI and ML research company specializing in developing novel industry-specific models allowing customers to bring domain knowledge, data and machine learning together.
www.desupervised.io
For more information, please contact
Johan Evenäs, +46464601291, johan.evenas@redglead.com
Michael Green, +4531766142, michael.green@desupervised.io
In this unique strategic partnership, Desupervised and Red Glead Discovery join forces to create robust AI-based solutions enabling companies to reduce cost and time in small molecule drug research and development.
Capitalizing on its proprietary AI-platform, Desupervised will leverage Bayesian deep learning models that quantify uncertainty for more reliable prediction of novel molecular structures for drug discovery projects. Such models need less data for training and enable domain knowledge inclusion, making drug discovery easier and faster. Currently, first-generation AI-tools that are being adopted by large Pharma companies require a significant investment in both implementing and operating such tools. Besides its technical advantages, AId (AId stands for a novel artificial intelligence-based tool for Drug Discovery) will be easy to implement also for smaller organizations to achieve significant improvement of workflows facilitated by AI technology.
Red Glead Discovery, providing integrated drug discovery services, has delivered several small molecule candidate drugs for progress to clinical trials in CNS and cancer indications to clients. Combining the partners´ expert knowledge from entirely different sectors, drug discovery and artificial intelligence (AI), the AId project aims at introducing an entirely new product to the market.
Johan Evenäs, CEO Red Glead Discovery AB says: “The collaboration with Desupervised fits perfectly with our strategy to become a leading and sustainable European drug discovery company. While RGD’s service platform increasingly attracts international biotech and large, global pharmaceutical companies, we are keen to extend and improve our service offer with AI technology. This project enables us to contribute with our expert knowledge in small molecule drug discovery to co-develop and implement state-of-the art AI tools, empowering us to better respond to future client needs.”
The CEO of Desupervised, Michael Green, adds: “I am delighted to be able to embark on this project, which will enable companies to innovate at greater speed utilizing AI and Machine Learning. We’ve always been about making AI usage accessible, robust and sustainable through our core Alvíss AI platform which is deployed in a variety of sectors today. In this project, we leverage the deep knowledge Red Glead Discovery has about the drug discovery process to build a new democratized drug discovery tool.”
About Red Glead Discovery AB
Red Glead Discovery is a leading Scandinavian provider for integrated drug discovery contract research and supports customers in the Life Science industry to develop their ideas for new drugs. www.redglead.com
About Desupervised ApS
Desupervised is a Nordic AI and ML research company specializing in developing novel industry-specific models allowing customers to bring domain knowledge, data and machine learning together.
www.desupervised.io
For more information, please contact
Johan Evenäs, +46464601291, johan.evenas@redglead.com
Michael Green, +4531766142, michael.green@desupervised.io
Read More